Journals / Türk Oftalmoloji Dergisi / 2017 / Cilt: 47 - Sayı: 6

The Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Macular Edema Related to Retinal Vein Occlusion: Real-life Data and Prognostic Factors in a Turkish Population

Retina Ven Tıkanıklığına Bağlı Maküla Ödemi Tedavisinde İntravitreal Deksametazon İmplantın Etkinliği ve Güvenirliği: Bir Türk Topluluğunda Gerçek Hayat Verileri ve Prognostik Faktörler

Pages
331–337
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The most powerful individual predictor of final visual acuity was baseline BCVA (r 2 =0.611, p

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To evaluate the efficacy and safety of dexamethasone (DEX) implants as mono or combination therapy for macular edema in retinal vein occlusion (RVO) with real-life conditions, and to detect factors that influence final visual acuity.
📊
Key Findings & Data:Materials and Methods: Twenty-five eyes with macular edema secondary to RVO underwent assessments for central macular thickness (CMT), best-corrected visual acuity (BCVA), adverse events, and also morphologic changes in optical coherence tomography at an interval of 4-8 weeks after at least one DEX implant.
💡
Conclusion & Impact:The most powerful individual predictor of final visual acuity was baseline BCVA (r 2 =0.611, p
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objectives: To evaluate the efficacy and safety of dexamethasone (DEX) implants as mono or combination therapy for macular edema in retinal vein occlusion (RVO) with real-life conditions, and to detect factors that influence final visual acuity. Materials and Methods: Twenty-five eyes with macular edema secondary to RVO underwent assessments for central macular thickness (CMT), best-corrected visual acuity (BCVA), adverse events, and also morphologic changes in optical coherence tomography at an interval of 4-8 weeks after at least one DEX implant. Results: Seventeen eyes with branch RVO and 8 eyes with central RVO were eligible for the study. The mean follow-up duration was 17 months (range, 12-26 months). Both mean BCVA (p=0.009) and CMT (p=0.006) improved significantly, and visual gains of ≥3 lines were achieved in 32% and ≥2 lines in 52% at the end of the follow-up period. The most powerful individual predictor of final visual acuity was baseline BCVA (r 2 =0.611, p

Özet

Amaç: Gerçek hayat koşullarında retina ven tıkanıklığına (RVT) bağlı maküla ödemi için tek başına veya kombine olarak uygulanandeksametazon (DEKS) implantın etkinlik ve güvenirliğinin değerlendirilmesi ve son görme keskinliğini etkileyen faktörlerin saptanması.Gereç ve Yöntem: RVT’ye bağlı maküla ödemine sahip 25 gözde en az bir DEKS implant sonrasında 4-8 haftalık aralıklarla yapılantakiplerde santral maküla kalınlığı (SMK), en iyi düzeltilmiş görme keskinliği (EİDGK) ve optik koherens tomografideki görünümdemeydana gelen değişiklikler ile ortaya çıkan yan etkiler değerlendirilmeye alındı.Bulgular: Retina ven dal tıkanıklığı için 17 göz, santral RVT için 8 göz çalışma için uygundu. Ortalama takip süresi 17 aydı (minimum12, maksimum 26). Takip süreci sonunda hem EİDGK (p=0,009) hem SMK (p=0,006) anlamlı bir şekilde düzeldi, ≥3 sıra görmekazancı olan gözlerin oranı %32 ve ≥2 sıra ve üzeri görme kazancı olan gözlerin oranı ise %52 idi. Son görme keskinliğini etkileyen engüçlü göstergenin bazal EİDGK olduğu (r 2 =0,611, p

🔖

Cite This Article

YAYLALI, S. A., AKÇAKAYA, A. A., SEVİMLİ, N., KANRA, A. Y., ALTINEL, M. G. (2022). The Efficacy and Safety of Intravitreal Dexamethasone Implant for the Treatment of Macular Edema Related to Retinal Vein Occlusion: Real-life Data and Prognostic Factors in a Turkish Population. Türk Oftalmoloji Dergisi, Cilt: 47 - Sayı: 6, 331–337. https://ajindex.com/articles/637864

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. Boyer DS, Yoon YH, Belfort R Jr, Bandello F, Maturi RK, Augustin AJ, Li XY, Cui H, Hashad Y, Whitcup SM; Ozurdex MEAD Study Group. Three- year, randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with diabetic macular edema. Ophthalmology. 2014;121:1904- 1914.
  2. Thakur A, Kadam R, Kompella UB. Trabecular meshwork and lens partitioning of corticosteroids: implications for elevated intraocular pressure and cataracts. Arch Ophthalmol. 2011;129:914-920.
  3. Chatziralli IP, Sergentanis TN, Sivaprasad S. Hyperreflectıve foci as an independent visual outcome predictor in macular edema due to retinal vascular diseases treated with intravitreal dexamethasone or ranibizumab. Retina. 2016;36:2319-2328.
  4. Farinha C, Marques JP, Almeida E, Baltar A, Santos AR, Melo P, Costa M, Figueira J, Cachulo ML, Pires I, Silva R. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome. Ophthalmic Res. 2015;55:10-18. Özdemir H. Serous macular detachment in retinal vascular disease. Ret-Vit. 2011;19:79-82.
  5. Wong IY, Iu LP, Koizumi H, Lai WW. The inner segment/outer segment junction: what have we learnt so far? Curr Opin Ophthalmol. 2012;23:210- 218. Coscas G, Coscas F, Zucchiatti I, Glacet-Bernard A, Soubrane G, Souied E. SD-OCT pattern of retinal venous occlusion with cystoid macular edema treated with ozurdex. Eur J Ophthalmol. 2011;21:631-636.
  6. Joshi L, Yaganti S, Gemenetzi M, Lightman S, Lindfield D, Liolios V, Menezo V, Shao E, Taylor SR. Dexamethasone implants in retinal vein occlusion: 12-month clinical effectiveness using repeat injections as-needed. Br J Ophthalmol. 2013;97:1040-1044.
  7. Capone A Jr, Singer MA, Dodwell DG, Dreyer RF, Oh KT, Roth DB, Walt JG, Scott LC, Hollander DA. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (Shasta study). Retina. 2014;34:342-351.
  8. Coscas G, Augustin A, Bandello F, de Smet MD, Lanzetta P, Staurenghi G, Parravano MC, Udaondo P, Moisseiev E, Soubrane G, Yatziv Y, Loewenstein A. Retreatment with Ozurdex for macular edema secondary to retinal vein occlusion. Eur J Ophthalmol. 2014;24:1-9.
  9. Pichi F, Specchia C, Vitale L, Lembo A, Morara M, Veronese C, Ciardella AP, Nucci P. Combination therapy with dexamethasone intravitreal implant and macular grid laser in patients with branch retinal vein occlusion. Am J Ophthalmol. 2014;157:607-615. Maggio E